Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1824293 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.47Day +2.80%Mkt cap $3M1Y −97.3%Off 52W high −98.2%Vol (1Y) 125.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 814 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest7.1% of sh out |
| Days to cover2.8d |
| 13F net flow (QoQ)−0.39% |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$10.9M |
| ROE−238.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−78.6% |
| 1Y−97.3% |
| 3Y−100.0% |
| Since incept. (ann.)−97.8% |
Total return through 2026-07-29 · series begins 2023-04-24. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)125.8% |
| Ann. volatility (3Y)150.6% |
| Sharpe (1Y)−2.23 |
| Sharpe (3Y)−1.83 |
| Max drawdown (1Y)−97.8% |
| Max drawdown (3Y)−100.0% |
| Beta (3Y vs SPY)−0.62 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 18,438 | $42,222 | 1.04% | −20.5% |
| UBS Group AG | 8,722 | $19,973 | 0.49% | new |
| Tower Research Capital LLC (TRC) | 1,060 | $2,427 | 0.06% | −62.9% |
| BlackRock, Inc. | 7 | $16 | 0.00% | −96.7% |
| SBI Securities Co., Ltd. | 4 | $9 | 0.00% | −96.6% |
| DANSKE BANK A/S | 2 | $5 | 0.00% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$1.61 | — | — | — |
| 2025-09-30 | 2025-11-14 | — | — | — | — |
| 2025-06-30 | 2025-08-14 | — | — | — | — |
| 2025-03-31 | 2025-05-15 | — | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
